NEW YORK, NY, UNITED STATES, April 1, 2026 /EINPresswire.com/ -- Çimsa, a subsidiary of Sabancı Holding and one of the ...
Full enrollment of BLA-enabling trial complete, per prior guidance –– Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission ...
MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow ...
The University of Colorado Anschutz Gates Institute has received Investigational New Drug clearance from the U.S. Food and Drug Administration, marking the first chimeric antigen receptor (CAR) T-cell ...
Oak Ridge National Laboratory researchers will share their discoveries and innovations at ARPA-E's Energy Innovation Summit ...
STAR-001 is identified for CNS indications by Lantern’s RADR AI platform. Credit: MY STOCKERS / Shutterstock.com. (MY ...
FDA NDA submission for bezuclastinib targets post-imatinib GIST, using Real-Time Oncology Review and supported by prior ...
How electric demolition machines provide mining operations with safe equipment options Alternative power is a worldwide trend ...
Designation granted by FDA recognizes the potential of plixorafenib, a novel, investigational paradox breaker and BRAF inhibitor, to provide substantial improvement over available therapies First ...
Datopotamab deruxtecan showed a 5.0-month OS improvement versus chemotherapy in first-line unresectable/metastatic TNBC ...
US FDA clears Lantern Pharma and Starlight Therapeutics’ IND for a planned phase 1 paediatric CNS cancer trial of STAR-001: Dallas Monday, March 30, 2026, 14:00 Hrs [IST] Lanter ...
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, has reached a significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results